Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during Toxoplasma gondii infection
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BMSCs are critical regulators of the hematopoietic response to inflammation through secretion of IL-6. Inflammation alters hematopoiesis, often by decreasing erythropoiesis and enhancing myeloid output. The mechanisms behind these changes and how the BM stroma contributes to this process are active areas of research. In this study, we examine these questions in the setting of murine Toxoplasma gondii infection. Our data reveal that infection alters early myeloerythroid differentiation, blocking erythroid development beyond the Pre MegE stage, while expanding the GMP population. IL-6 was found to be a critical mediator of these differences, independent of hepcidin-induced iron restriction. Comparing the BM with the spleen showed that the hematopoietic response was driven by the local microenvironment, and BM chimeras demonstrated that radioresistant cells were the relevant source of IL-6 in vivo. Finally, direct ex vivo sorting revealed that VCAM+CD146lo BM stromal fibroblasts significantly increase IL-6 secretion after infection. These data suggest that BMSCs regulate the hematopoietic changes during inflammation via IL-6.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Interleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Relatively recent literature has established a critical function for IL-6, which can act through hepcidin to reduce iron availability and restrict erythropoiesis [5–9].”
BackgroundSacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., Tagliafico, E., Ferrari, S., Robey, P. G., Riminucci, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.025 · Cited by 2,226
Self-citationPronk, C. J. H., Rossi, D. J., Månsson, R., Attema, J. L., Norddahl, G. L., Chan, C. K. F., Sigvardsson, M., Weissman, I. L., & Bryder, D. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.07.005 · Cited by 671 · cited 1×
“It further supports a hepcidin and iron-independent mechanism for IL-6, as the Pre MegE stage occurs before transferrin receptor up-regulation [29].”
BackgroundHepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466 · cited 5×
“Whether IL-6 limits erythropoiesis independently of hepcidin in vivo remains an important question, as therapies specifically neutralizing IL-6 and hepcidin are being developed for use in clinical settings [11, 12].”
BackgroundInfluentialHunter, C. A., Chizzonite, R., & Remington, J. S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.9.4347 · Cited by 245
Song, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood · doi:10.1182/blood-2010-03-271791 · Cited by 228
Ueda, Y., Cain, D. W., Kuraoka, M., Kondo, M., & Kelsoe, G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803961 · Cited by 138 · cited 1×
“This myeloerythroid shift occurs in multiple models of inflammation, from bacterial infection to sterile immunization [1–4], and is one pathway that leads to the common condition of anemia in the setting of inflammation.”
BackgroundAnemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin
Hohaus, S., Massini, G., Giachelia, M., Vannata, B., Bozzoli, V., Cuccaro, A., D'Alo', F., Larocca, L. M., Raymakers, R. A. P., Swinkels, D. W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6873 · Cited by 110 · cited 1×
“A recent study of Hodgkin’s lymphoma patients also concluded that IL-6 was functioning via an alternative mechanism, as anemia correlated with serum IL-6 but not hepcidin [33].”
Background
Cited by
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G., & Morrison, S. J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.06.008 · Cited by 1,381
“, 2007) or CD146 with platelet-derived growth factor receptor b (PDGFRb), CD106, NG2, or some combination thereof (Chou et al., 2012; Crisan et al., 2008; Schwab and Gargett, 2007).”
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Huang, B., Lang, X., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023177 · Cited by 479
Bianco, P. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013132 · Cited by 402
Immune response and immunopathology during toxoplasmosis
Dupont, C. D., Christian, D. A., & Hunter, C. A. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0339-3 · Cited by 359
Metadata
- Authors
- Chou, D. B., Sworder, B., Bouladoux, N., Roy, C. N., Uchida, A. M., Grigg, M., Robey, P. G., & Belkaid, Y.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-01
- Volume
- 92
- Issue
- 1
- Pages
- 123-131
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2138493215
- Cited by
- 71
- References
- 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.